# US 2020/0392476 A1 · Multilayer nano-cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392476 A1
- Document ID: US20200392476A1
- Status: Published application
- Kind: A1
- Application number: 16/996,457
- Filed: 2020-08-18
- Published: 2020-12-17
- Earliest claimed: 2019-05-22
- Inventors: Boke ZHANG
- Web page: https://patentgrep.com/patent/US20200392476A1

## CPC

- C12N 9/52: derived from bacteria {or Archaea}
- A61K 9/113: Multiple emulsions, e.g. oil-in-water-in-oil {(A61K9/0026 takes precedence)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/728: Hyaluronic acid
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- B01D 15/362: {Cation-exchange}
- B01D 15/363: {Anion-exchange}
- B01D 61/244: {comprising multiple dialysis steps}
- C07K 14/33: from Clostridium (G)
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- B01D 2311/02: Specific process operations before starting the membrane separation process
- B01D 2311/04: Specific process operations in the feed stream; Feed pretreatment
- B01D 2311/06: Specific process operations in the permeate stream
- B01D 2311/2623: Ion-Exchange
- B01D 2311/2688: Biological processes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A multilayer nano-cell includes an innermost water phase core including biomolecules in an aqueous solution; a first layer, including an oil phase layer encapsulating the innermost water phase core, thereby forming a water-in-oil structure, the oil phase layer including caprylic/capric triglyceride and macrogol-35-glycerol-rizinoleat; a second layer, including a water phase layer encapsulating the first layer, the water phase layer including hyaluronic acid, Cu-GHK tripeptide, palmitoyl-KTTKS pentapeptide, and hexapeptide argireline; a third layer, including another oil phase layer encapsulating the second layer; a fourth layer, including another water phase layer encapsulating the third layer; a fifth layer, including another oil phase layer encapsulating the fourth layer; and a sixth layer, including an outmost cream layer encapsulating the fifth layer.

## Claims

### Claim 1

A multilayer nano-cell, comprising:
an innermost water phase core including biomolecules in an aqueous solution, the biomolecules including hyaluronic acid, and the aqueous solution including Cu-GHK tripeptide, palmitoyl-KTTKS pentapeptide, and hexapeptide argireline;
a first layer, including an oil phase layer encapsulating the innermost water phase core, thereby forming a water-in-oil structure, wherein the oil phase layer includes caprylic/capric triglyceride and macrogol-35-glycerol-rizinoleat;
a second layer, including a water phase layer encapsulating the first layer, the water phase layer including hyaluronic acid, Cu-GHK tripeptide, palmitoyl-KTTKS pentapeptide, and hexapeptide argireline;
a third layer, including another oil phase layer encapsulating the second layer;
a fourth layer, including another water phase layer encapsulating the third layer;
a fifth layer, including another oil phase layer encapsulating the fourth layer; and
a sixth layer, including an outmost cream layer encapsulating the fifth layer.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The multilayer nano-cell according to claim 1, wherein:
the multilayer nano-cell has an average size ranging from about 10 nanometers to about 100 nanometers.

### Claim 4 (depends on 1)

The multilayer nano-cell according to claim 1, wherein:
an average size of the water-in-oil structure is in a range of 3 nanometers to 20 nanometers.

### Claim 5 (depends on 1)

The multilayer nano-cell according to claim 1, wherein:
the outmost cream layer includes a water phase mixture and an oil phase mixture,
the water phase mixture includes at least one of glycerin, dipotassium glycyrrhizate, petylene glycol, propylene glycol, methylparaben and carbomer, and
the oil phase mixture includes at least one of mineral oil, cetearyl alcohol, propylparaben, methylparaben, polyethylene glycol (PEG)-100 stearate, PEG-40 hydrogenated castor oil, caprylic/capric triglyceride, polysorbate-80, macrogol-35-glycerol-rizinoleat, glyceryl stearate, polysorbate-65, polysorbate-60, polysorbate-20, soybean oil, tea oil, vegetable oil, sunflower seed oil, fish oil, sesame oil, vitamin E, animal lipid oil, octanoic acid decanoic acid ester of glycerol, lecithin egg phosphatidylcholine (EPC), poly(propyleneoxide) (PPO), poly(D, L-lactic acid) (PDLLA), poly(ε-caprolactone) (PCL), poly(L-aspartate) and poloxamers, PEG-polyglutamate, PEG-polyaspartate, PEG-poly-L-lactide, sorbitane monopalmitate, and sorbitan oleate.

### Claim 6 (depends on 1)

The multilayer nano-cell according to claim 1, wherein:
the another water phase layer includes hyaluronic acid, Cu-GHK tripeptide, palmitoyl-KTTKS pentapeptide, and hexapeptide argireline; and
each of the another oil phase layers includes caprylic/capric triglyceride and macrogol-35-glycerol-rizinoleat.

### Claim 7 (depends on 1)

The multilayer nano-cell according to claim 1, wherein:
each of the another oil phase layers further includes one or more of hydrogenated castor oil, Caprylic/capric triglyceride, polysorbate, soybean oil, sorbitan oleate, vitamin E, mineral oil, cetearyl alcohol, propylparaben, methylparaben, polyethylene glycol (PEG-100) stearate.

### Claim 8 (depends on 1)

The multilayer nano-cell according to claim 1, wherein:
the water phase layer in the second layer further includes one or more of, cell growth factors, stem cells, stem cell liquids, peptides, proteins, aptamers, oligo-nucleotides, vitamins, Snap-8 octapeptide, di-peptides, allantoin, niacinamide, aloe vera, Co-enzymes, resveratrol, palmitoyl-KTTKS, palmitoyl-GHK, palmitoyl-GQPR, palmitoyl-oligopeptides, aptamers, si-RNAs, stem cells, botulinum neurotoxin, and therapeutic agents.

### Claim 9 (depends on 8)

The multilayer nano-cell according to claim 8, wherein:
the therapeutic agents include one or more selected from insulin, celecoxib, rofecoxib, 5-floro-uracil, diacarbazine, ibuprofen, tetracycline, oxytetracycline, estriol, progesterone, doxycycline, minocycline, estradiol, silver ions including AgNO3, Zn ions including ZnO, and plant extracts.

### Claim 10 (depends on 1)

The multilayer nano-cell-according to claim 1, wherein:
the first layer of the multilayer nano-cell provides a particle size distributed from 7.04 nm to 15.3 nm by a volume distribution;
the second layer of the multilayer nano-cell provides a particle size distributed from 8.47 nm to 23.7 nm by a volume distribution;
the third layer of the multilayer nano-cell provides a particle size distributed from 12.5 nm to 29.9 nm by a volume distribution;
the fourth layer of the multilayer nano-cell provides a particle size distributed from 16.1 nm to 33.4 nm by a volume distribution;
the fifth layer of the multilayer nano-cell provides a particle size distributed from 17.0 nm to 52.8 nm by a volume distribution; and
the six layer of the multilayer nano-cell provides a particle size distributed from 18.0 nm to 61.1 nm by a volume distribution.
